John Libbey Eurotext

Personalized treatment with retigabine for pharmacoresistant epilepsy arising from a pathogenic variant in the KCNQ2 selectivity filter Volume 23, numéro 5, October 2021

Illustrations

  • Figure 1
  • Figure 2
  • Figure 3

Tableaux

Auteurs
1 Pediatric Neurology Unit, Edmond and Lilly Safra Pediatric Hospital, Chaim Sheba Medical Center, Tel ha Shomer, Israel
2 Pediatric Neurology Unit, Edith Wolfson Medical Center, Holon, Israel
3 Pediatric Department, The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
4 Physiology Department, The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
* Correspondence: Andreea Nissenkorn Pediatric Neurology Unit, Edith Wolfson Medical Center, Holon, Israel

The neuronal M channels, belonging to the voltage-gated potassium channel Kv7 family, have emerged as critical players in epilepsy [1, 2]. Assembled as heterotetramers of Kv7.2 and Kv7.3 subunits, M channels generate subthreshold, non-inactivating voltage-gated K+ currents that play an important role in controlling neuronal excitability [1, 3-7]. Pathogenic variants in the KCNQ2 gene, encoding for the Kv7.2 channel subunit, were initially linked to benign familial neonatal epilepsy [8, 9], but later [...]